Post-Covid condition and clinic characteristics associated with SARS-CoV-2 infection: a 2-year follow-up to Brazilian cases

Abstract

Until January 2023, Brazil recorded 37 million COVID-19 cases despite the decrease in mortality due to mass vaccination efforts against COVID-19. The infection continues to challenge researchers and health professionals with the persistent symptoms and onset manifestations after the acute phase of the disease, namely Post-Covid Condition (PCC). Being one of the countries with the highest infection rate, Brazil must prepare for a growing number of patients with chronic health consequences of COVID-19. Longitudinal studies that follow patients over extended periods are crucial in understanding the long-term impacts of COVID-19, including potential health consequences and the effects on quality of life. We describe the clinical profile of a cohort of COVID-19 patients infected during the first year of the pandemic in Brazil and a follow-up after two years to investigate the health impacts of SARS-CoV-2 infection. The first wave of SARS-CoV-2 infection in Brazil featured extensive drug misuse, notably the ineffective COVID kit comprised of ivermectin, antimalarials and azithromycin, and elevated in-hospital mortality. In the second phase of the study, Post-Covid Condition was reported by symptomatic COVID-19 subjects across different severity levels two years after infection. Long haulers are more likely to be women, previously hospitalized, and reported a range of symptoms from muscle pain to cognitive deficit. Our longitudinal study is essential to inform public health authorities to develop strategies and policies to control the spread of the virus and mitigate its impacts on society.

Effects of pharmacotherapy on post-COVID-19 pulmonary fibrosis: Systemic review

“…Another work reported association of antibiotics (including beta-lactams) consumption with the higher risk of death in critical patients (beta-lactam: RR = 17.49, 95% CI:4.49-68.12, p < 0.001; other antibiotics: RR = 1.84, 95% CI: 1.39-2.44, p < 0.001) suggesting worsening of respiratory function and possible risks of pulmonary sequelae [16]. One clinical trial reported significant (<0.05) improvement of COVID-19 symptoms and reduction of inflammatory markers (lactate dehydrogenase (LDH), ferritin, and C-reactive protein (CRP) -LF predictors) in case of use of a combination of aspirin, promethazine, vitamin D3, C, and B3 along with zinc and selenium supplementation compared to the control group [17].…”

Promosi Kesehatan Untuk Meningkatkan Kualitas Hidup Pasca Menderita Infeksi Covid-19

“…Hasil evaluasi dari 16 studi yang dilakukan di berbagai negara dan menemukan bahwa pasien pasca COVID-19 mengalami penurunan kualitas hidup yang Fahrun Nur Rosyid, Promosi Kesehatan untuk… signifikan (Figueiredo et al, 2022). Studi yang dilakukan da Silva et al (2023), di Brazil menunjukkan bahwa pasien COVID-19 yang sembuh dapat mengalami gejala paska COVID yang beragam dan berlangsung selama minimal 2 bulan setelah infeksi. Temuan tersebut relevan dengan hasil penelitian sebelumnya yang menyebutkan bahwa meskipun seseorang dinyatakan sembuh dari infeksi COVID-19 dalam kurun waktu satu tahun mengalami gejala persisten berupa keletihan dan dyspnea sebesar 50-87%, sebanyak 22% mengalami depressi, nyeri dada 21.7% dan nyeri sendi 27.3% (Abdelrahman et al, 2021).…”

Qualidade de Vida Relacionada à Saúde e Resultados em Longo Prazo após Covid-19 Levemente Sintomático: Explorando o Protocolo

“…O Brasil é um país que oferece um excelente campo de estudo para esse problema de saúde, pois possui uma das maiores incidências de Covid-19 no mundo. 9 Os estudos brasileiros abrangeram amostras regionalizadas 10 - 13 e estudos longitudinais com observação de curto período ou desenhos transversais, 11 , 14 Rover et al pretendem analisar a população brasileira além do período de estudo de um ano. 8 Porém, não serão incluídos centros da região Nordeste, e apenas um centro da região Centro-Oeste e um centro da região Norte serão incluídos, colocando-se assim uma limitação ao estudo.…”

“…8 Brazil is a country that provides an excellent field of study for this health issue, as it has one of the highest incidences of COVID-19 in the world. 9 Brazilian studies have covered regionalized samples [10][11][12][13] and longitudinal studies with a short period observation or cross-sectional designs. 11,14 Rover et al intend to analyze the Brazilian population in addition to the one-year study period.…”